Objective Oesophageal adenocarcinoma (OA) incidence has risen sharply in Western countries over recent decades. Local and systemic inflammation is considered an important contributor to OA pathogenesis. Established risk factors for OA and its precursor, Barrett's oesophagus (BE), include symptomatic reflux, obesity and smoking. The role of inherited genetic susceptibility remains an area of active investigation. Here, we explore whether germline variation related to inflammatory processes influences susceptibility to BE/OA. Design We used data from a genomewide association study of 2515 OA cases, 3295 BE cases and 3207 controls. Our analysis included 7863 single-nucleotide polymorphisms (SNPs) in 449 genes assigned to five pathways: cyclooxygenase (COX), cytokine signalling, oxidative stress, human leucocyte antigen and nuclear factor-κB. A principal components-based analytic framework was employed to evaluate pathway-level and gene-level associations with disease risk. Results We identified a significant signal for the COX pathway in relation to BE risk ( p=0.0059, false discovery rate q=0.03), and in gene-level analyses found an association with microsomal glutathione-Stransferase 1 (MGST1); ( p=0.0005, q=0.005). Assessment of 36 MGST1 SNPs identified 14 variants associated with elevated BE risk (q<0.05). Four of these were subsequently confirmed ( p<5.5×10
INTRODUCTION
The incidence of oesophageal adenocarcinoma (OA) has risen rapidly over recent decades in Western countries. 1 2 OA typically arises within a metaplastic precursor epithelium known as
Significance of this study
What is already known on this subject?
▸ Local and systemic inflammation are considered important contributors to the pathogenesis of Barrett's oesophagus (BE) and oesophageal adenocarcinoma (OA). ▸ Inherited genetic variation in inflammation-related pathways and genes may modulate the functional intensity of inflammatory signalling networks. ▸ Small-scale candidate gene-based studies suggest possible associations between inflammation-related genetic variation and altered risk of BE/OA.
What are the new findings?
▸ Germline variation in the cyclooxygenase (COX) pathway is associated with altered risk of BE, based on analysis of the largest available consortium genomewide association study data set for this condition. ▸ The pathway-level association signal for COX and risk of BE appears to be driven in part by variation at the microsomal glutathione S-transferase 1 (MGST1) gene locus. ▸ Several intronic single-nucleotide polymorphisms with strong regulatory potential (expression quantitative trait loci) at the MGST1 locus exhibit significant associations with risk of BE, with confirmation in a large independent sample set.
Barrett's oesophagus (BE). 3 Established risk factors for OA and BE include symptomatic GORD, abdominal adiposity, tobacco smoking, European ancestry and male sex. [3] [4] [5] A prevailing conceptual model has linked chronic inflammation and genomic instability to OA pathogenesis. 3 Several exposures associated with elevated disease risk, such as GORD, obesity and smoking, increase levels of local and systemic inflammation, while use of non-steroidal anti-inflammatory drugs (NSAIDs) and statins has been associated with reduced risk. [6] [7] [8] It remains poorly understood, however, whether and to what extent inherited genetic variation in specific genes and pathways implicated in inflammatory signalling may modulate disease susceptibility and interact with these established risk factors.
A biological link between chronic inflammation and cancer risk has long been appreciated. 9 10 Inflammation may act at multiple stages of disease development to disrupt tissue homeostasis, induce aberrant proliferative responses, modulate the tumour microenvironment and compromise immune surveillance. 11 12 Inflammatory physiological changes such as oxidative stress are known to exert downstream genotoxic effects, 13 and when sustained over extended periods, can promote the emergence of cancer-initiating mutations. In the oesophagus, longterm exposure to gastric acid or bile salts results in the release of pro-inflammatory cytokines (eg, interleukin-8 (IL-8)), activation of nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and cyclooxygenase-2 (COX2), and direct tissue damage to the squamous epithelium. [14] [15] [16] Cigarette smoking can also expose the oesophagus to deleterious toxins while simultaneously inducing systemic inflammatory responses based on activation of cytokine signalling, NF-κB activation and COX pathway stimulation. [17] [18] [19] Abdominal adiposity and obesity have been associated with elevated circulating levels of pro-inflammatory mediators such as tumour necrosis factor-α, C reactive protein, IL-6 and leptin. 20 Recent large-scale genomewide association studies () have provided comprehensive assessments of genetic susceptibility to BE and OA. [21] [22] [23] [24] [25] Novel associations have been identified with variants in or near several transcription factors implicated in embryonic oesophageal development, a transcriptional coactivator and the human leucocyte antigen (HLA) region. It remains likely, however, that additional loci that did not satisfy the commonly used, stringent statistical threshold ( p<5×10 −8 ) may be involved in modifying disease risk. In this regard, pathway-based analytic methods can offer significant advantages over conventional genomewide analyses by simultaneously reducing the number of statistical comparisons and increasing power via aggregating large numbers of low-magnitude signals; 26 such methods allow for the systematic analysis of coherent biological processes most likely implicated in disease aetiology.
Given the central role of inflammation in BE and OA pathogenesis, we examined genetic variation in five inflammationrelated pathways-COX, cytokine signalling, oxidative stress, HLA and NF-κB-using a principal components analysis (PCA)-based framework. Using genotyping data from the International Barrett's Esophagus and Adenocarcinoma Consortium (BEACON) GWAS of 2515 OA cases, 3295 BE cases and 3207 controls, we selected 7863 single-nucleotide polymorphisms (SNPs) in 449 genes and assessed associations with risks of BE and OA in a pre-specified tiered fashion, first at the pathway level, next at the gene level and ultimately at the SNP level.
METHODS

Study population and SNP genotyping
The BEACON GWAS included individuals diagnosed with OA or BE, and control participants pooled from 14 individual studies conducted in Western Europe, Australia and North America, as described previously. 21 The current analysis employed a pooled data set 27 that included participants of European ancestry from the BEACON GWAS, additional patients with BE and OA from the UK Barrett's Esophagus Gene Study and the UK Stomach and Oesophageal Cancer Study (SOCS), respectively, 21 and additional control participants from a hospital-based case-control study of melanoma conducted at the MD Anderson Cancer Center (Houston, Texas, USA). 28 Genotyping of buffy coat or whole-blood DNA from all participants was conducted using the Illumina Omni1M Quad platform, in accordance with standard quality control procedures. 29 All participants gave written informed consent, and this project was approved by the ethics review board of the Fred Hutchinson Cancer Research Center. We selected all unrelated participants with <2% missing genotyping calls, as described previously. 21 The final study sample included 2515 OA cases, 3295 BE cases and 3207 controls. Three control participants were excluded from analyses involving BE cases because of familial relation to cases.
Selection of genes in inflammation-related pathways
Five pathways implicated in chronic inflammation were selected for analysis: (1) COX (n=40 genes), (2) pro-inflammatory and anti-inflammatory cytokines (n=198 genes), (3) oxidative stress (n=117 genes), (4) HLA (32 genes) and (5) NF-κB (n=125 genes). Selected genes (see online supplementary table S1) were identified based on an extensive survey of the prior literature on inflammation in cancer and OA pathogenesis, 11 30-34 and as described in public databases (eg, KEGG, Biocarta).
SNP selection
SNPs selected for this study are located in or near (±2.0 kb) the genes chosen for analysis. We included only those SNPs that passed Illumina quality measures and standard quality control procedures, 29 as previously described, 21 and had a minor allele frequency of ≥1%. Imputation of missing values for genotyped SNPs was conducted using SHAPEIT. 35 After imposing the above filters, we identified all available Omni1M SNPs located within the selected genes. Segments of 2.0 kb of flanking sequence proximal to the transcriptional start sites and distal to Significance of this study How might it impact on clinical practice in the foreseeable future?
▸ Our data identify the MGST1 gene as a novel susceptibility locus for BE. These findings further enhance our understanding of the biological pathways that likely underlie differential susceptibility to this cancer precursor lesion in human populations. Such insights will contribute to the ongoing effort to develop comprehensive population-based risk assessment tools for BE that integrate behavioural, clinical and genetic data to identify and target individuals at highest risk of disease for preventive interventions.
the 3 0 untranslated regions were also included, based on gene boundaries defined in hg19/GRChB37. No Omni1M SNPs were available for 16 genes initially selected (cytokines: n=14, oxidative stress: n=2) (see online supplementary table S1). Minor and major alleles were reported throughout using the 'plus' strand designation.
Statistical analysis
We examined each of the five inflammation-related pathways using an application of PCA 36 (see online supplementary figure S1). We first constructed a genotype matrix comprising all SNPs assigned to the indicated pathway, inclusive of case patients of the selected type (BE or OA) and all control participants. Individual SNP variables, coded as 0, 1 or 2 minor alleles, were standardised across participants to have a mean of 0 and SD of 1. The first N principal components (PCs) that captured ≥50% of the genotypic variance of the pathway were selected. Association between a given pathway and risk of BE or OA was assessed using the likelihood ratio test (LRT). Two logistic regression models were compared: (i) a full model containing N pathway-level PCs (PC 1,p …PC N,p ), age, sex and the first four PCs derived from ancestry-informative markers (AIMs) to account for population stratification (PC 1,AIM -PC 4,AIM ); 27 and (ii) a reduced model containing only age, sex and PC 1,AIM -PC 4,AIM . HLA loci were excluded from the set of AIMs, as described previously. 21 We selected pathways for which the resulting LRT p value was <0.05, after correction for multiple comparisons (n=5) via the false discovery rate (FDR) method (see online supplementary figure S1, step 1).
To prioritise genes within a selected pathway for further analysis at the gene level, we examined SNP loading factors within the first pathway-level PC (PC 1,p ). SNPs within PC 1,p were rank-ordered by the absolute values of their loading coefficients. The first 10 genes represented by these rank-ordered SNPs were advanced to gene-level analysis (see online supplementary figure S1, step 2). PCA was conducted for each of these genes using a genotype matrix comprised of all SNPs assigned to the indicated gene; the first N PCs that captured ≥50% of the genotypic variance were selected. Association between a given gene and risk of BE or OA was assessed as above using the LRT, comparing (i) a full model inclusive of the selected gene-level PCs (PC 1,g -PC N,g ), age, sex and PC 1,AIM -PC 4,AIM ; and (ii) a reduced model containing age, sex and PC 1,AIM -PC 4,AIM . Multiple comparisons (n=10) were accounted for via the FDR method (see online supplementary figure S1, step 3).
Genes satisfying FDR q<0.05 were selected for additional analysis at the SNP level. Unconditional logistic regression was used to compute ORs for risk of BE or OA associated with a given SNP variant under an additive model ( per-allele) with adjustment for age, sex and PC 1,AIM -PC 4,AIM , and correcting for multiple comparisons via the FDR method (see online supplementary figure S1, step 4). Observed associations were visualised graphically using LocusZoom. 37 Gene-environment interactions were investigated using a subset of the overall study population for which exposure data were available; BE/OA case patients from SOCS and the UK BE Gene Study, and control participants from MD Anderson were excluded. Reflux symptoms, body mass index (BMI), smoking history and NSAID use were defined as follows: reflux/heartburn: ≥weekly symptoms (yes or no); BMI: <25, 25-29, 30-34 or 35+; smoking: ever or never, or pack-years: 0, 1-14, 15-29, 30-44 or 45+; NSAID use: ever or never. Pack-year smoking history and BMI were modelled as continuous covariates in tests for interaction. All PCA-based statistical analyses, as well as SNP-based tests and interaction studies, were conducted using STATA/SE V.14 (College Station, Texas, USA).
Validation studies
An independent data set comprised of 1851 patients with BE and 3496 control participants from the UK, described previously 22 was used for validation studies. Summary statistics for the associations of 13 genotyped SNPs at the MGST1 locus and risk of BE were extracted and used in a subsequent meta-analysis based on the inverse-variance weighting method. 38 Validation analyses were conducted in R V.3.2.1.
RESULTS
Characteristics of study participants
The distributions of demographic and behavioural characteristics among control participants, BE case patients and OA case patients are shown in table 1. OA cases were somewhat older and more often male compared with controls and BE cases. The percentage reporting ever having smoked cigarettes was higher among BE and OA cases than among controls, and heavy smoking (45+ pack-years) was more prevalent among OA cases. Obesity (BMI 30+) and weekly reflux/heartburn were more prevalent among BE and OA cases than among controls. NSAID use appeared similarly common across the three groups.
Pathway-level associations with risk of BE or OA To obtain a top-level, global assessment of the association between germline variation within five selected inflammationrelated pathways (COX, cytokine signalling, oxidative stress, HLA and NF-κB) and risk of BE or OA, we employed a PCA-based approach (see online supplementary figure S1). Based on logistic regression analyses that incorporated a subset of the derived PCs as predictor variables and assessed associations with disease risk, we identified a single significant ( p<0.05) pathway-level signal for risk of BE: the COX pathway ( p=0.006) (table 2) . This association remained significant after accounting for multiple comparisons (FDR q=0.03). None of the five pathways examined were found to be associated ( p<0.05) with risk of OA.
Gene-level associations with risk of BE
To determine whether the observed pathway-level signal for COX could be further localised to particular individual genes, we undertook gene-level analyses using the same PCA framework (see online supplementary figure S1). Of the 40 genes assigned to the COX pathway, we prioritised 10 for further analysis, as prespecified in our analysis plan. The top 10 genes were selected based on their contribution to the overall pathway-level genotypic variance, as reflected in rank-ordered SNP loading coefficients in the first PC. Among these 10 genes assessed for associations with risk of BE ( figure S2) ; modest-to-moderate LD was observed between rs2239676, the top-ranked SNP in this second region and the other five variants in close proximity. Among the 14 significant SNP-level signals identified for BE, 8 were also associated with increased risk of OA (p<0.05, q<0.05), with observed ORs ranging from 1.10 to 1.17 (see online supplementary table S3).
Assessment of top MGST1 SNPs and risk of BE in an independent study sample
We next evaluated whether any of the 14 MGST1 variants associated with risk of BE showed similar associations in a large, independent sample set from the UK comprised of 1851 patients with BE and 3496 control participants. Also, 13 of the 14 SNPs were available for analysis, and four 3 0 variants exhibited borderline-significant ( p<0.10) associations with BE: rs3852575, rs4149204, rs7312090 and rs4149203 (table 5) . ORs for these SNPs were similar to those obtained in the primary analysis, though slightly reduced in magnitude (1.08 vs 1.16). In a subsequent meta-analysis, the p values for all four of these variants were highly significant ( p<5.5×10 −5 ), with an additional six SNPs satisfying p<0.05.
Assessment of gene-environment interactions
We next conducted stratified analyses and evaluated interactions between several risk factors for BE/OA (smoking, obesity, reflux and NSAID use) and the top MGST1 variants (q<0.01) associated with risk of BE. No statistically significant interactions were observed (data not shown).
DISCUSSION
Chronic inflammation may occur as a result of multiple exposures established as risk factors for BE and OA (gastrooesophageal reflux, obesity, smoking) and is thought to represent a common pathway underlying the emergence and progression of these conditions. 3 39 This study represents the first systematic examination of the relationship between germline genetic variation in inflammation-related pathways-COX, cytokine signalling, oxidative stress, HLA and NF-κB-and risks of BE and OA. Drawing on genetic data from a large consortium-based GWAS, 21 we found a significant association between variation in the COX pathway and risk of BE, and identified a gene-level signal for MGST1. Four individual MGST1 variants were associated with elevated disease risk, including several intronic variants subsequently confirmed ( p<5.5×10 −5 ) in a meta-analysis encompassing a large independent sample set of additional BE cases and controls.
MGST1 is one of three MGST enzymes in humans and belongs to a larger GST gene family encoding a number of proteins that neutralise oxidative stress through conjugation of endogenous and xenobiotic lipophilic electrophiles with glutathione. [40] [41] [42] MGST1 shares ∼40% sequence homology at the amino acid level with prostaglandin E synthase (PTGES, formerly MGST1L1), a key enzyme that acts downstream of COXs to catalyse the production of PGE 2 from PGH 2.
43 MGST1-3 and PTGES belong to the 'MAPEG' superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism. Microsomal GST1 is localised to the endoplasmic reticulum and outer mitochondrial membrane, and plays an important role in suppressing lipid peroxidation and protecting mitochondrial integrity. 41 Multiple alternatively spliced transcripts arise from the MGST1 gene locus, and the MGST1 promoter region has been shown to be transcriptionally responsive to oxidative stress. 40 Some evidence exists for an association between genetic variation in the MGST1 gene and altered risk of colorectal cancer in Han Chinese. 44 The 14 MGST1 SNPs found to be associated with risk of BE in our primary analysis were geographically clustered into two main groups, one at the 3 0 end of the gene and the other at the 5 0 end. The most significant association was for rs4149203 C>T, a 3 0 intronic variant in strong LD with six other associated 3 0 SNPs (r 2 >0.8). Four of these seven SNPs, including rs4149203, were confirmed in the meta-analysis phase of our validation studies. These variants modify predicted sequence motifs for several transcription factors (eg, POU5F1, SOX, BRCA1, FOXP1) 45 and have been described as strong expression quantitative trait loci (eQTLs) for MGST1 in whole blood (see online supplementary table S4). 46 Of interest, FOXP1 was previously identified as a susceptibility locus for BE/OA. 21 25 At the 5 0 end of MGST1, rs2239676 C>G was the top signal identified among a cluster of six associated variants. Three of these SNPs lie in close proximity to the MGST1 transcriptional start site, within a region characterised as active chromatin in oesophageal tissue (see online supplementary figure S3). One of these SNPs (rs2975138), as well as an upstream variant (rs4149186), represents a strong eQTL for MGST1 in oesophageal mucosa. 47 Given that these 5 0 variants were not confirmed in the Oxford (UK) data set, however, their association with BE risk remains questionable.
Our findings suggest that several of the identified variants may play a role in influencing MGST1 RNA expression levels. Additional studies, however, are warranted to investigate experimentally potential associations between selected variants and altered tissue-specific MGST1 expression, and to explore a possible causal basis for the observed findings. Data from the Genotype-Tissue Expression Project (GTEx) further indicate that a number of MGST1 variants not included in our present analysis are also strong cis-eQTLs in oesophageal mucosa; 47 imputed genotypes were available for 25 of these 29 eQTLs, but did not show significant ( p<0.05) associations with disease risk (data not shown). Whether the other four MGST1 eQTLs exhibit associations with BE remains to be evaluated. Since BE and OA often arise within an epithelium chronically exposed to refluxate and to cigarette-associated toxins (ie, associated with inflammation), it would be of interest to determine whether MGST1 plays a protective biological role in counteracting such insults and maintaining tissue homeostasis. In this regard, we note that past studies have provided support for cytosolic GSTs and glutathione peroxidases carrying out such functions in the oesophagus and have implicated epigenetic silencing of these genes as a feature of BE/OA pathogenesis. 48 Given that BE is the only known precursor of OA, one expectation is that risk factors linked to altered risk of BE would be associated with similar alterations in risk of OA. In this study, variation in the COX pathway as a whole met the threshold for significance in relation to risk of BE, but not OA. A number of the individual MGST1 SNPs associated with risk of BE, however, did exhibit similar associations with risk of OA (see online supplementary table S3). With respect to top SNP-level signals, the associated ORs for OA were in the same direction as, and of comparable magnitude to, those observed for BE. This strong level of concordance suggests that the identified variants, if causal, may influence disease risk primarily at the level of BE rather than progression from BE to OA. Previous candidate gene-based studies have reported associations between germline variation in PTGS2 (COX-2) and altered risk of OA, 49 50 while independent evidence has supported an inverse association between use of NSAIDs (inhibitors of COX-1 and COX-2 activity) and risk of OA. 6 7 Our gene-level and SNP-level analyses did not include all genes assigned to the COX pathway (eg, PTGS2) as only a limited subset were advanced for further study based on pre-specified selection criteria (the top 10 genes in PC1, see table 3). It remains possible that associations of disease risk with variation in other COX pathway genes may be evident in our data set and contribute in part to the observed pathway-level signal.
One of the strengths of our study was the use of a PCA framework to assess pathway-level and gene-level associations between germline genetic variation and risk of BE or OA. PCA is an effective strategy to reduce data dimensionality. 36 In this report, we adapted PCA to genetic pathway and gene analysis, and implemented a hierarchical strategy to identify genetic variants associated with traits. Application of PCA to GWAS data offered key advantages over conventional marginal analyses that are based exclusively on evaluation of individual SNPs. First, by aggregating signals across multiple genes (of a given pathway) or across multiple SNPs (of a given gene), the PCA method increased our ability to detect associations characterised by multiple, independent, distributed low-magnitude signals. Second, by reducing the dimensionality of the genotype matrix, PCA appreciably reduced the number of multiple comparisons and effectively increased our statistical power.
Another important strength was the use of pooled data from the BEACON GWAS, which provided the largest sample size to date in the evaluation of inflammation-related germline variation and risks of BE and OA. As a consequence of analysing both BE and OA, we had the opportunity to compare genetic variation associated with risk of a neoplastic precursor lesion and the cancer that arises from it. While our main findings were limited to BE, individual variants of the MGST1 gene were also significant for risk of OA. Our pooled assessment of 7863 SNPs in 449 genes assigned to five pathways significantly expands past candidate gene-based efforts to examine genetic variation in inflammation-related loci in relation to risk of BE and OA. Finally, our use of an external independent data set from the UK helped further strengthen the identified signal at MGST1.
This study also had certain limitations. First, while our tiered analysis scheme enabled us to restrict the number of comparisons and boost statistical power, it also narrowed the scope of our analysis and potentially resulted in missed association signals. Variation in four of the five included pathways was not examined at the gene or SNP level, while only 25% of the genes in the COX pathway were advanced beyond pathway-level assessment. Second, given the hierarchical nature of our statistical analysis, whereby we first assessed significance at the pathway level, and then proceeded to the gene level only for 'significant' pathways, the initial p values obtained for individual genes, and subsequently for individual SNPs, should be interpreted as the p values conditional on that pathway (or gene) already being selected, that is, P(A|B), where B represents the event that a pathway (or gene) is selected and A represents the event that a gene (or SNP) is significant. This conditional probability framework was well suited to our use of PCA as a discovery-phase approach for identifying novel associations for subsequent confirmation in an independent sample set. Third, missing data for smoking, obesity, reflux and NSAID use in a sizable fraction of participants reduced our statistical power to evaluate gene-environment interactions, underscoring the need for further studies using expanded sample sets. Fourth, while our study provided broad coverage of several major biological pathways of probable relevance to BE/OA, it is almost certain that a number of important genes or genomic loci were not included. Cytokine signalling, NF-κB activity and oxidative stress, for example, represent complex processes likely influenced by many hundreds or more gene products and a large number of intergenic loci harbouring both enhancer/insulator transcriptional elements and non-coding RNAs. The present analysis was restricted to examining common germline variants located within or in close (2.0 kb) proximity to defined proteincoding genes.
In conclusion, our study represents the most comprehensive evaluation to date of inflammation-related inherited genetic variation in relation to risk of BE and OA. Using a PCA framework for pathway-level and gene-level analyses, we describe evidence for novel associations between variation at the MGST1 locus and increased risk of BE. It appears plausible that certain associated variants may act to influence expression levels of MGST1, a gene with known roles in the cellular response to oxidative stress. Pending further validation in additional study populations, future studies are warranted to fine-map the identified association signals, assess experimentally the functional effects of these variants and explore the biological role of MGST1 in BE/OA pathogenesis.
A case of heart failure and diarrhoea
CLINICAL PRESENTATION
A 20-year-old man with no significant medical history presented with a 5-day history of intermittent chest pain and dyspnoea. He also reported a 3-month history of daily diarrhoea characterised by multiple, loose, watery, non-bloody stools. Physical examination was notable for tachycardia and a soft systolic murmur at the apex. Laboratory evaluation was significant for microcytic anaemia (serum iron 17 μg/dL; normal range 50-150 μg/dL) and an NT-proBNP (N-terminal pro-brain natriuretic peptide) of 18 995 pg/mL (normal <51 pg/mL). A colonoscopy with random biopsies for evaluation of diarrhoea was unremarkable. Esophagogastroduodenoscopy demonstrated a scalloped and mosaic pattern in the second and third portions of the duodenum ( figure 1A) , while biopsies showed a malabsorption pattern with total villous atrophy, increased intraepithelial lymphocytes and crypt hyperplasia (figure 1B). During hospitalisation, the patient experienced 2:1 heart block and non-sustained ventricular tachycardia. Transthoracic echocardiogram demonstrated an ejection fraction of 21% and severe generalised global hypokinesis. Cardiac MRI demonstrated myocardial delayed enhancement in a non-coronary distribution including right ventricular, mid-myocardial ( figure 1C ; white arrows) and apex ( figure 1D ; white arrow) suggestive of myocarditis. Right ventricular biopsy (figure 2) showed lymphocytic infiltration (white arrow), injured myocytes (white arrowheads), myocyte hypertrophy (black arrow) and interstitial fibrosis (black arrowheads).
QUESTIONS
What is the most likely diagnosis? What are the options for management? 
